Form ARS Imunon, Inc. For: Dec 31
Tweet
Share
E-mailATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Imunon to present IMNN-001 ovarian cancer data at AACR conference
- Samsung Epis Holdings Reports Second Quarter and Half-Year 2026 Financial Results
- IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
